From: NRS 449 on behalf of Natalie Yanish
To: NRS449@LISTSERV.STATE.NV.US
Subject: Technical Bulletin - De-authorization of 2023-2024 COVID-19 Vaccines and Emergency Use Update
Date: Wednesday, October 2, 2024 12:01:41 PM

FDA Approves and Authorizes for Emergency Use Updated COVID-19 Vaccines and De- authorizes Administration of 2023-2024 COVID-19 Vaccines

Technical bulletin provides information on updated guidance for vaccinations.

The Nevada Division of Public and Behavioral Health's Nevada State Immunization Program has authored a technical bulletin with information regarding the status of disposal of discontinued vaccination doses, and which individuals are recommended to receive the 2024-2025 Novavax COVID-19 Vaccine, Adjuvanted.

On August 22, 2024, the U.S. Food and Drug Administration (FDA) issued approval and granted emergency use authorization (EUA) to both Moderna and Pfizer-BioNTech for their updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. This is to provide the public with an updated mRNA COVID-19 vaccine formulary that more closely targets currently circulating variants and provides better protection against serious illness and complications from COVID-19.
In addition, from correspondence received from the Centers for Disease Control and Prevention (CDC) on August 23, 2024, all 2023-2024 mRNA COVID-19 vaccines are no longer authorized for use in the United States, regardless of age. Administration of any 2023-2024 mRNA COVID-19 vaccines are now considered vaccine administration errors and must be reported to the Vaccine Adverse Event Reporting System (VAERS). To minimize the risk of vaccine administration errors, providers should:

- Remove all 2023–2024 mRNA COVID-19 vaccines from storage units immediately, even if they are not expired.
- Once all inventory is fully accounted for, delete 2023–2024 mRNA COVID-19 vaccine listings from the available vaccine inventory in your Immunization Information System, as applicable.
- Return **all unused 2023–2024 mRNA COVID-19 vaccines** to CDC's centralized distributor

using the normal process for returning spoiled/expired vaccines.

On August 30, 2024, the FDA amended Novavax's COVID-19 Vaccine EUA to include their 2024-2025 vaccine formula. The Novavax COVID-19, Adjuvanted (2024-2025 formula) includes a monovalent (single) component that corresponds to the Omicron variant JN.1 strain of SARS-CoV-2 for use in individuals 12 years of age and older. In addition to this authorization, FDA also de-authorized the 2023-2024 Novavax COVID-19 Vaccine, Adjuvanted for use in the United States.

The technical bulletin provides full information about the Nevada Division of Public and Behavioral Health (DPBH) recommendations. To access the bulletin, see the "COVID-19" section of the Technical Bulletins web page linked here.
